Summary
- Profile Type
- Technology offer
- POD Reference
- TOHU20250606012
- Term of Validity
- 6 June 2025 - 6 June 2026
- Company's Country
- Hungary
- Type of partnership
- Commercial agreement with technical assistance
- Research and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A Hungarian university offers a novel, non-invasive bioimpedance-based technology for breast cancer detection. Validated in animal models with 97% measurement accuracy, this solution improves diagnostic precision without tissue damage. The organisation seeks partners for research or commercial agreements with technical assistance.
- Full Description
-
A Hungarian university, active in biomedical innovation, has developed a novel diagnostic technology based on multifrequency electrical impedance tomography (EIT) for the detection of breast tumors. This method represents a new dimension in imaging, capable of providing more accurate diagnostic results than traditional imaging technologies.
The background challenge addressed by this innovation is the early and accurate detection of malignant tumors, which remains one of the most critical global healthcare issues. Breast cancer is the leading cause of cancer-related deaths among women worldwide, including in Hungary, where over 60,000 new cancer cases are diagnosed yearly and more than 2,000 women die annually from breast cancer.
Unlike conventional imaging, the developed technology:
- Utilizes multifrequency bioimpedance measurements.
- Is non-invasive and does not damage tissue.
- Achieves 97% accuracy in animal model trials.
- Has been validated with high-reliability datasets using advanced data processing technology.
The technology is already patented in Japan, the USA, Germany, France, Switzerland, the UK and Hungary.
The university seeks research cooperation agreements or commercial agreements with technical assistance to further develop the technology, conduct clinical trials, or support market deployment. - Advantages and Innovations
-
- Non-invasive diagnostic method with no tissue damage.
- High accuracy (97%) proven in preclinical animal models.
- Advanced data analysis technology used to process the bioimpedance signals.
- Applicable as a complementary diagnostic tool to existing imaging techniques.
- Legally cleared for use in multiple international markets. - Stage of Development
- Lab tested
- Sustainable Development Goals
- Goal 9: Industry, Innovation and Infrastructure
- Goal 3: Good Health and Well-being
- IPR status
- IPR granted
- IPR notes
- Patent granted in Japan, the USA, Germany, France, Switzerland, the United Kingdom, and Hungary.
Partner Sought
- Expected Role of a Partner
-
The university is seeking:
- Medical technology companies to support clinical validation and market launch under a commercial agreement with technical assistance.
- Research institutions or hospitals interested in joint development or clinical trials under a research cooperation agreement.
Ideal partners should have experience in medical diagnostics or imaging technologies and the capacity to engage in collaborative R&D or clinical evaluation. - Type and Size of Partner
- Big company
- SME 11-49
- University
- R&D Institution
- SME 50 - 249
- Type of partnership
- Commercial agreement with technical assistance
- Research and development cooperation agreement
Dissemination
- Technology keywords
- 06001012 - Medical Research
- 06001003 - Cytology, Cancerology, Oncology
- 06001005 - Diagnostics, Diagnosis
- Market keywords
- 05001001 - Diagnostic services
- 05002005 - Other medical imaging
- 05004005 - Diagnostic equipment
- Sector Groups Involved
- Health
- Targeted countries
- All countries
